Age-related macular degeneration (AMD) is referred to as the leading cause of irreversible visual loss in developed countries, with a profound effect on the quality of life. The neovascular form of AMD is characterized by the formation of subretinal choroidal neovascularization, leading to sudden and severe visual loss. Research has identified the vascular endothelial growth factor (VEGF) as an...

The hallmark feature of the wet or neovascular form of age-related macular degeneration is the presence of choroidal (or retinal) neovascularization (CNV). If left untreated, CNV may result in significant central vision loss due to complications including exudation, leakage, and ultimately subretinal fibrosis causing remarkable photoreceptor loss. Although the mechanism of development is not fu...

BACKGROUND To report the occurrence of foveal atrophy and macular hole formation following intravitreal ranibizumab with or without photodynamic therapy for choroidal neovascularization caused by age-related macular degeneration. METHODS This was a retrospective, interventional case series, in which 78 eyes of 76 patients were treated for wet age-related macular degeneration between February ...

Bevacizumab (Avastin(®)) has been used by ophthalmologists in many countries as an off-label drug for the treatment of wet age-related macular degeneration (AMD). Due to its short half-life necessitating frequent intravitreal injection, a method for sustained delivery is in need. We demonstrated that bevacizumab could be released in a sustained fashion over 90 days from nano- and microspheres f...

Conbercept is a genetically engineered homodimeric protein for the treatment of wet age-related macular degeneration (wet AMD) that functions by blocking VEGF-family proteins. Its huge, highly variable architecture makes characterization and development of a functional assay difficult. In this study, the primary structure, number of disulfide linkages and glycosylation state of conbercept were ...

Age-related macular degeneration (AMD) is the leading cause of visual loss in the developed World in patients over age 55. Therapeutic advances in the dry (non-exudative) form of AMD have been very modest with a protective role demonstrated for supplemental anti-oxidant vitamin therapy in patients showing high risk characteristics for future progression. In contrast, a major advance in the trea...

Distillers byproducts are excellent feed resources for feedlot cattle. Distillers byproducts are normally available for use in feedlot finishing diets in two forms, dried distillers and wet distillers byproducts (WDB). In general, there are two nutritional philosophies regarding their use in feedlot finishing diets. Distillers byproducts can be fed at 6 to 15% of the diet dry matter, serving pr...

Age-related macular degeneration (AMD) is a leading cause of irreversible visual impairment in the world. Advanced AMD can be divided into wet AMD (choroidal neovascularization) and dry AMD (geographic atrophy, GA). Drusen is characterized by deposits in the macula without visual loss and is an early AMD sign in the Caucasian population. rs11200638 in the promoter of HTRA1 has recently been sho...

purpose : to evaluate the toxic retinal effects of intravitreal bevacizumab used for the treatment of exudative age-related macular degeneration (amd) using ganzfeld electroretinography (g-erg) methods : in this prospective comparative interventional study, 23 patients with active choroidal neovascularization (cnv) associated with amd were enrolled. patients were received intravitreal injection...

PURPOSE To define the frequency and quantify the progression of macular atrophy (MA) in patients with neovascular age-related macular degeneration undergoing treatment with antivascular endothelial growth factor therapy for >2 years. METHODS Fifty-four eyes of 46 patients (86.7 ± 6.8 years, 53.7% women) diagnosed with wet age-related macular degeneration were included in this retrospective st...